Project Grant R43AA033295
Award Date 9/1/26
Completion Date 2/28/27
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Westminster, CO 80234, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $576,197 on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop and test a digital pill system paired with smartphone-delivered cognitive behavioral therapy to measure and support acamprosate adherence in individuals with alcohol use disorder and alcohol-associated liver disease. Yale will develop a user-centered adherence intervention called ACAMPROSYNC that combines a digital pill system...
- The National Institute on Alcohol Abuse and Alcoholism awarded RTI International $1,759,221 on September 20, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop small molecule modulators of RXFP3 as therapeutic agents for alcohol use disorder. RTI International will optimize lead-like RXFP3 negative allosteric modulator (NAM) compounds to improve potency and absorption, distribution, metabolism, and excretion/pharmacokinetic properties, then evaluate their effects in animal models...
- The National Institute on Alcohol Abuse and Alcoholism awarded $293,684 to Remedi, Inc. on July 20, 2026, under the Alcohol Research Programs funding mechanism (CFDA 93.273) to develop an oral formulation of dimethyltryptamine (DMT) co-formulated with CX157, a proprietary reversible monoamine oxidase-A inhibitor, for treating alcohol use disorder. Remedi is addressing a critical pharmacokinetic barrier to DMT therapy: rapid degradation by monoamine oxidase when administered orally, which...
- The National Institute on Alcohol Abuse and Alcoholism awarded Envisbio LLC $390,454 on September 15, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop aptamers that modulate phosphodiesterase 4B (PDE4B) for treatment of alcohol use disorder. The Phase I Small Business Innovation Research grant funds two specific research aims: screening and identification of aptamers that bind to PDE4B in human and rat models, and functional testing of identified aptamers in cell-based...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
- The National Institute on Alcohol Abuse and Alcoholism awarded Creare LLC $314,357 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop a wearable sensor system for continuous monitoring of alcohol withdrawal syndrome. The project delivers a real-time bracelet-based device integrating tremor detection, heart rate variability, sleep tracking, and sweat ethanol sensing with a machine learning algorithm that synthesizes multiple physiological inputs into a continuous...
- The National Institute on Alcohol Abuse and Alcoholism awarded Brown University $1,429,670 on September 18, 2025, under the Alcohol Research Programs (CFDA 93.273) to conduct a 12-week, double-blind, randomized controlled trial testing probenecid as a treatment for alcohol use disorder. The study enrolls 120 individuals with alcohol use disorder and compares probenecid (2 grams daily) to placebo across three primary aims: reducing acute alcohol craving in an alcohol cue reactivity procedure,...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Johns Hopkins University $616,371 under the Alcohol Research Programs (CFDA 93.273) on June 10, 2026, to conduct a double-blind randomized controlled trial testing daridorexant, a dual orexin receptor antagonist, for reducing alcohol craving and use and improving total sleep time in patients with alcohol use disorder and co-occurring sleep disturbance. Participants recruited from a residential treatment facility will be...
- The National Institute on Alcohol Abuse and Alcoholism awarded Psilera, Inc. $2,629,049 on September 15, 2025, to characterize a novel non-hallucinogenic psilocybin derivative for alcohol use disorder treatment under the Alcohol Research Programs (CFDA 93.273). Psilera will develop a selective serotonergic-targeting psilocybin derivative with reduced hallucinogenic properties as a therapeutic candidate for alcohol use disorders. The company has conducted structure-activity relationship...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Washington University $555,331 on August 13, 2026, under the Alcohol Research Programs (CFDA 93.273) to examine the metabolic-epigenetic regulation of alcohol intake and associated molecular mechanisms. The funded research explores how alcohol-derived acetate generated during alcohol metabolism affects brain histone acetylation and subsequently influences alcohol intake behavior. The project builds on preliminary findings...